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Introduction
Currently, there is little doubt that activation of the
neuroendocrine (NE) system is predominately responsible
for the progressive decline of heart function in heart failure
(HF). This is due to the complex action of neurotransmitters,
hormonal factors, and/or immunological pathways.
Evidence that supports this point of view is the clear
prognostic benefit and the reduction of HF progression by
using NE-guided therapeutic approaches (SOLVD
investigators 1992; Eichhorn and Bristow 1996; Packer et
al 1996; Opie 2004; Solomon et al 2004). However, the fact
that HF represents one of the major causes of morbidity
and mortality in Western countries also suggests that the
current portfolio of NE antagonists fails to completely
explain and possibly counteract disease progression (Guyatt
and Deveraux 2004). In this context, interest in the
relationship between thyroid hormones (THs) and HF is
increasingly gaining prominence. The chief reason for the
latter is the emerging novel actions of THs on the
cardiovascular system and, more specifically, the role of
TH as a prognostic biomarker of cardiac disease as well
as the potential benefit of TH administration in patients
with HF.
Thyroid hormones in cardiac performance and
vascular tone: new evidence
Thyroid hormones and, in particular, the active form
triiodothyronine (T3) regulate the synthesis and action of
various cardiac proteins including α and β myosin heavy
chain (α-MHC and β-MHC, respectively), sarcoplasmic
reticulum Ca2+-ATPase (SERCA), Na+/Ca2+ exchanger
(NCX), phospholamban, and voltage gated potassium
channels (Klein and Ojamaa 2001). The fundamental actions
of TH on the cardiovascular system are well documented
not only by the large series of experimental data (Klein and
Ojamaa 2001) but also by the more recent evidence of
cardiovascular alterations in the presence of minimal
changes of thyroid function in humans. We recently utilized
magnetic resonance (MR) and tagging MR to evaluate
cardiac morphology and function in patients with mild
(subclinical) chronic hypothyroidism (SHT). We were able
to demonstrate altered cardiac volumes and resting global
and regional systolic performance of the left ventricle in
SHT patients as compared with normal subjects. TH
replacement therapy reversed the alteration to normal in SHT
patients (Ripoli et al 2005). The association of reduced pre-
load with increased after-load, observed in SHT in this study,
is in line with the multidistrict effect of TH (Klein and
Ojamaa 2001) by which central (cardiac) and peripheral
(vascular) effects act synergically to improve systolic
performance. The observed changes in pre- and after-load
are sufficient to explain the decrease of systolic pump
performance observed in SHT patients without the need to
invoke a simultaneous direct impairment in myocardial
inotropic function. Accordingly, for similar values of end-
systolic volumes, systolic arterial pressure did not differ
among patient subgroups and the control group, thus
suggesting a similar degree of contractility (Ripoli et al
2005). On the basis of the above considerations, regional
changes of systolic function, observed with tagging MR,
might be interpreted just as the result of parallel changes in
cardiac loading conditions. Future studies, however, will
be helpful to define the clinical impact in terms of symptoms
and outcome of these abnormalities in patients with heart
failure showing abnormal peripheral TH metabolism
characterized by low levels of biologically active form T3.
A close relationship between thyroid function and blood
pressure physiology was also found by the use of an in vivo
human model of short-term, severe hypothyroidism
(Fommei and Iervasi 2002). TH withdrawal induced an
increase in blood pressure levels, particularly diastolic
pressure. The deprivation of TH was associated to a
proportional increase in plasma noradrenaline and
adrenaline, whereas the restoration of thyroid function
abolished that stimulation and proportionally reduced blood
pressure levels, thus indicating that TH contribute to
systemic arterial blood pressure homeostasis. Accordingly,
a direct relaxant effect of the TH on cultured arteriolar
smooth muscle cells was also reported in recent years
(Ishikawa et al 1989). Moreover, exposure to T3 of vascular
smooth muscle cells isolated from rat aorta caused theseVascular Health and Risk Management 2005:1(2) 98
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cells to relax rapidly; this effect was independent from
cAMP and nitrix oxide formation (Ishikawa et al 1989;
Ojamaa et al 1996).
More recently, we evaluated the role of T3 and thyroxine
(T4) on the hamster cheek pouch microcirculation. The
application of T3 consistently induced dose-dependent
dilation of arterioles within 2.0 ± 0.5 min from adminis-
tration. The application of T4 caused dilation within
16 ± 2 min. Iopanoic acid, which inhibits both 5´-type 1
deiodinase and 5´-type 2 deiodinase, abolished the dilation
elicited by T4 but did not affect T3-dependent dilation.
6-propyl-2-thiouracil, which inhibits 5´-type 1 deiodinase
but does not alter T3 production from T4 by 5´-type 2
deiodinase, did not affect the dilation induced by T4. Thus,
local conversion of T4 to T3 represents a crucial step for
the dilation of the microcirculatory system, which can be
now considered a target for a TH action (Colantuoni et al
2004).
Thyroid hormone and heart failure
Changes in thyroid metabolism characterized by a reduction
in biologically active T3 have been reported in HF (Klein
and Ojamaa 2001) and commonly interpreted as a
compensatory mechanism. The hypothesis that this
alteration is an adaptive factor minimizing catabolic
phenomena of illness has been recently questioned since
there is evidence of a negative prognostic impact of this
syndrome in patients with heart diseases and specifically in
patients with HF. For example, in a cohort of 573 unselected
cardiac patients, the probability of death was significantly
higher in patients with low T3 syndrome; free (F)T3 resulted
also in a powerful independent predictor of cardiac and
cumulative death (Iervasi et al 2003). In a more recent study
on patients with non-ischemic and ischemic HF, T3 levels
represented an important predictor of mortality, which added
prognostic power to conventional cardiac parameters
(Pingitore et al 2005). Kaplan-Meyer survival curves of
patients with reduced left ventricular ejection fraction
(LVEF) and total (T) T3 showed the highest mortality when
compared with that of patients with similar LVEF but normal
total TT3, indicating thereby the power of TT3 concentration
in discriminating patients at very high risk for death (Figure
1a, 1b). These results well fit with the very recent observation
of a relationship between FT3/FT4 ratio, echocardiographic
alterations, and mortality in patients with dilated
cardiomyopathy (Kozdag et al 2005), and reinforce previous
data in a smaller cohort of patients showing the potential
capacity of prognostic stratification of the altered TH
metabolism in HF (Hamilton et al 1990). Moreover, these
results favor the experimental evidence that an altered TH
metabolism may not be interpreted just as a biological risk
factor of death but as a direct causal factor contributing to
the progression of HF. At the same time, all the above
mentioned clinical data fit well with the observation in a
human model of cultured atrial cardiomyocites and
myocardial tissue, that normal T3 has a critical role in
maintaining morpho-structure and calcium handling (Forini
et al 2001). The absence of T3 leads to disorganization of
cultured myocardium and phenotypical remodeling which
resembles gross and cellular structural impairment observed
during HF progression (Glennon et al 1995; Mann 1999;
Forini et al 2001). Following the same line of reasoning it
is interesting to remark that changes in gene expression and
cardiac function observed in heart disease match those seen
in hypothyroidism (Brent et al 1991; Ojamaa et al 1992;
Kiss et al 1994; Wickenden et al 1997; Oudit et al 2001;
Yen 2001) and coincide with the so-called recapitulation of
the fetal phenotype (Izumo et al 1987; Colucci 1997;
Haghighi et al 2001).
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Figure 1 (a) Kaplan-Meier 18-month survival curves of the patients with left
ventricular ejection fraction > 20%, divided according to the low limit of normal
range of TT3 (1.2 nmol/L). (b) Kaplan-Meier 18-month survival curves of the
patients with left ventricular ejection fraction ≤ 20%, divided according to the
low limit of normal range of TT3 (1.2 nmol/L). Data adapted from Pingatore et al
(2005).
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Treatment of heart failure with synthetic
thyroid hormone
A strong argument in favor of the hypothesis that a low T3
state may contribute to the poor prognosis of HF patients
comes from data showing the benefit gained from treating
patients with synthetic TH. Unfortunately, only a few studies
have tested the synthetic T4 or T3 as a potentially beneficial
treatment of cardiac dysfunction (Klemperer et al 1995;
Hamilton et al 1998). From the first observation (Gay et al
1988), it was clear that one of the major limitations of the
hypothesis would have been the plethora of noncardiac
collateral effects induced by the hormone such as the
increase in oxygen consumption and heart rate as well as
negative effects on protein and fat metabolism. Interestingly,
in humans, three studies evaluated the possibility of using
T3 and T4 therapeutically with the purpose of improving
cardiac function of HF avoiding the unwanted detrimental
effects (Moruzzi et al 1996; Hamilton et al 1998; Iervasi et
al 2001). In the first two studies (whether intravenous
infusion [IV] of supraphysiological doses of T3 for 6 hours
was used or treatment with 0.1 mg of T4 was given daily for
12 weeks, respectively), there was an increase in cardiac
output associated with a decrease in systemic vascular
resistance (Moruzzi et al 1996; Hamilton et al 1998). The
more recent pilot study from our laboratory (Iervasi et al
2001) also provided data on the safety and efficacy of long-
term (96 hours) IV T3 replacement (ie, 20 µg·die·m2) therapy
in patients with low T3 syndrome and severe chronic HF. A
significant increase in cardiac output with unchanged heart
rate was already observed after 24 hours of T3 infusion
together with a progressive increase in LVEF and a reduction
in systemic vascular resistance. Most importantly, the
improvement in the cardiovascular (and renal) hemo-
dynamics was also associated with a progressive increase
in 24-hour urinary output and a reduction in noradrenaline
plasma levels. The interpretation of the results is, however,
largely affected by the small cohort of patients enrolled in
all studies (Moruzzi et al 1996; Hamilton et al 1998; Iervasi
et al 2001), the absence of a sufficiently long period of
observation and, with the exception of the Moruzzi’s study,
the lack of randomization.
An alternative approach to the problem could be the use
of TH analogs with fewer side effects, and among these,
the more emerging 3,5-diiodothyropropionic acid (DITPA)
(Pennock et al 1992; Morkin et al 2004), which has shown
to have cardiac inotropic selectivity and minimal effects on
heart rate and metabolic activity. Several studies (Pennock
et al 1993; Mahaffey et al 1995; Wickenden et al 2000)
confirmed in various animal models the beneficial effects
of the drug on HF and peripheral resistance, and they have
formed the basis for a large clinical trial in HF patients with
low T3, which is currently in progress (Morkin et al 2004).
Perspectives and conclusions
There are increasing experimental and clinical findings that
strongly support the fundamental role of TH in the
cardiovascular homeostasis both in physiological and
pathological conditions. In particular, clinical data (Kozdag
et al 2005; Pingitore et al 2005) seem to suggest that an
altered TH metabolism characterized by a reduced level of
biologically active T3 or FT3/FT4 ratio may contribute to
poor prognosis. An important issue that needs further
exploration is the relationship between TH and the other
NE systems activated in HF. Additional pathophysiological
studies in animal models and in humans are needed to
improve our knowledge on the positive and/or negative
effects of an altered thyroid metabolism in HF. Moreover,
large, multicenter, placebo controlled prospective studies
could provide fundamental data on safety and prognostic
effects of the chronic treatment with TH replacement therapy
using T3 and/or T4 or TH analogs. Important issues include
a clear definition of primary and secondary, clinically
relevant end points (ie, mortality, hospitalization, quality of
life, side effects etc) as well as type, dosage, and schedule
of treatment.
At the same time, the more recent finding of a consistent
5´-type 2 deiodinase gene expression and activity in the
cardiovascular system (Croteau et al 1996; Mizuma et al
2001) suggests new potential lines of investigation. The
existence in the microcirculatory system of a deiodinating
pathway that is able to produce local T3 and the documented
vasodilating activity of neo-generated T3 (Colantuoni et al
2004) are fundamental findings in defining the vascular
system as a direct target of TH. Taken together, these data
could open the way to new therapeutic perspectives
involving novel molecular and pharmacological strategies.
For example, a recent experimental approach was used to
overexpress 5´-type 2 deiodinase gene in the cardiac
myocytes to increase the cellular action of TH (Pachucki et
al 2001). Even though all the target genes of TH action in
vascular smooth muscle cells are still unknown, similar
approaches perhaps could be employed as a new strategy
to regulate systemic vascular resistance during progression
of HF.Vascular Health and Risk Management 2005:1(2) 100
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